BioArctic AB’s partner Eisai announced the publication of additional detailed analyses from the phase 2b clinical study, evaluating the efficacy and safety of lecanemab for mild cognitive impairment due to Alzheimer’s disease and mild AD.
BioArctic AB’s partner Eisai announced the publication of additional detailed analyses from the phase 2b clinical study, evaluating the efficacy and safety of lecanemab for mild cognitive impairment due to Alzheimer’s disease and mild AD.